Drogsan Pharmaceuticals
Drogsan Pharmaceuticals is a Turkish generic pharmaceutical manufacturer founded in 1975, producing prescription drugs, food supplements, and cosmetics across 10+ therapeutic areas for domestic and 30+ international markets through cGMP-certified manufacturing, licensing, and partnership-based distribution.
- Company typePrivate
- Founded1975
- HeadquartersBalgat
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Drogsan Pharmaceuticals does
Drogsan Pharmaceuticals (legal name: Drogsan İlaçları Sanayi ve Ticaret A.Ş.) is a Turkey-based generic pharmaceutical manufacturer founded in 1975 by Pharmacist Nevzat Karpuzcu, operating as a member of the Nevzat Group conglomerate. The company manufactures and sells generic prescription pharmaceuticals, food supplements, and cosmetic products across more than 10 therapeutic areas including dermatology, nephrology, neurology, infectious diseases, gastroenterology, otorhinolaryngology, dentistry, gynecology, urology, and internal medicine. Manufacturing follows cGMP standards and ICH Quality by Design guidelines at a facility in Çubuk, Ankara, with production capacity of 19 million boxes (solid dosage), 6.9 million boxes (liquid 1), and 11.5 million boxes (liquid 2) annually. R&D operations are housed at Gazi Teknopark since 2015.
The company operates a B2B pharmaceutical distribution model, selling through wholesalers, pharmacies, and hospitals in Turkey, and exporting to more than 30 countries across CIS, Southern Europe, Middle East, Central Asia, Southeast Asia, and Africa through licensing agreements, technology transfers, co-marketing, and co-development partnerships. Revenue streams include product sales (generics, food supplements, cosmetics) and licensing/technology transfer income. The company holds 200+ international product licenses and has received regulatory approvals from health authorities in the GCC, Saudi Arabia, UAE, Kuwait, Uganda, and the Philippines. Notable milestones include launching Turkey's first domestically produced biosimilar in 2014 (nephrology), commercializing the Storice patented dermatological formulation with Cumhuriyet University in 2018, and achieving TURQUALITY brand certification in 2021.
Total Nevzat Group turnover is USD 400 million with 1,400 employees across healthcare sector operations; pharmaceutical pricing is regulated by Turkish government authorities and is not publicly disclosed. The Karpuzcu family retains control through Chairman/CEO Mustafa Karpuzcu and Deputy Chairman Emin Karpuzcu, with founder Nevzat Karpuzcu serving as Honorary Chairman. Strategic partnerships include Rockwell Medical (hemodialysis iron therapy), Cumhuriyet University (Storice formulation), LG Chem, and Douglas Pharmaceuticals.
Drogsan Pharmaceuticals firmographics
Firmographics- Name
- Drogsan Pharmaceuticals
- Legal name
- Drogsan İlaçları Sanayi ve Ticaret Anonim Şirketi
- Website
- https://drogsan.com.tr
- Company type
- Private
- Founded year
- 1975
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Drogsan Pharmaceuticals is a Turkish generic pharmaceutical manufacturer founded in 1975, producing prescription drugs, food supplements, and cosmetics across 10+ therapeutic areas for domestic and 30+ international markets through cGMP-certified manufacturing, licensing, and partnership-based distribution.
- Ownership category
- akta.pro rank
Drogsan Pharmaceuticals industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
- akta.pro secondary industries
- Generic Hospital & Institutional Products (HLAIABAL), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)
Keywords
Where Drogsan Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Balgat
Offices4 records
Markets served
Drogsan Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Generic Pharmaceutical Products: Revenue from manufacturing and selling generic/generic equivalent drugs across therapeutic areas including dermatology, nephrology, neurology, internal medicine, infectious diseases, gastroenterology, otorhinolaryngology, dentistry, gynecology and urology.
- Food Supplements: Revenue from nutritional and dietary supplement products developed and manufactured by the company.
- Cosmetic Products: Revenue from cosmetic product development and sales including dental and personal care products.
- Licensing and Technology Transfer: Revenue from licensing agreements, technology transfers, co-marketing, co-development, and marketing authorization transfers for the Turkish market and export markets.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
Drogsan Pharmaceuticals product offering
Product offeringCore offering
Drogsan Pharmaceuticals manufactures and markets generic and innovative pharmaceutical products across 21 therapeutic categories including antiviral, cardiovascular, respiratory, gastrointestinal, dermatological, neurological, and nephrology treatments. The company operates cGMP-compliant manufacturing facilities producing solid dosage forms (tablets, capsules, sachets) and liquid preparations (syrups, nasal sprays, oral solutions) for distribution through wholesalers, pharmacies, hospitals, and international partners across 30+ countries.
Product overview
Drogsan Pharmaceuticals is a Turkish pharmaceutical company established in 1975, operating as part of Nevzat Group with 1,400 employees and USD 400 million in revenue. The company manufactures prescription pharmaceuticals across 21 therapeutic categories including cardiovascular, antiviral, respiratory, gastrointestinal, dermatological, neurological, nephrology, and food supplements. Key products include Abavir (antiviral), Amlovas (cardiovascular), Baravir (antiviral), Bicana (respiratory), Colidur Fort (gastrointestinal), and the patented Storice (dermatological) formulation. Drogsan operates cGMP-compliant manufacturing facilities producing solid dosage forms (tablets, capsules, sachets - 19M boxes), liquid preparations including oral/nasal sprays (6.9M boxes), and syrups/solutions (11.5M boxes). The company exports to 30+ countries including East/South Europe, CIS, Middle East, Africa, and Asia. In 2014, Drogsan launched Turkey's first domestic biosimilar in nephrology. R&D activities at Gazi Teknopark focus on generic drug development following ICH guidelines.
Differentiator
Problem solved
Functional benefit
Brands
- Storice: Strontium + Licorice based patented dermatological formulation for skin care, commercialized in partnership with Cumhuriyet University.
- Omega Royal
Products and services
- Abavir 245 mg Film Coated Tablet Antiviral medication containing Tenofovir Disoproxil Fumarat used in the treatment of viral infections; available in 30 and 90 tablet pack sizes for prescription dispensing.
- Amlovas Tablet (5 mg / 10 mg) Cardiovascular medication containing Amlodipine Besylate, a calcium channel blocker used to treat hypertension and angina; available in 20, 30, and 90 tablet pack sizes.
- Avanose Nasal Spray Combination nasal spray containing Fluticasone Propionate and Azelastine Hydrochloride for allergic rhinitis treatment; delivered as suspension in 30 ml pump bottle.
- Baravir Film Coated Tablet (0.5 mg / 1 mg) Antiviral medication containing Entecavir Monohydrate used for hepatitis B treatment; available in 30 tablet pack sizes.
- Bicana Syrup Respiratory medication containing Terbutaline Sulphate and Guaifenesin for cough and respiratory conditions; packaged in 100 ml bottles.
- Colidur Fort 550 mg Film Coated Tablet Gastrointestinal antibiotic containing Rifaximin for the treatment of traveler's diarrhea and other intestinal conditions; available in 42 tablet pack.
- Dentasave Whitening Toothpaste Dental care product for tooth whitening; packaged in 75 ml tubes.
- Storice Facial Cleansing Gel Facial cleansing gel for sensitive skin containing Strontium and Licorice extracts; first patented formulation from a Turkish medical faculty to be commercialized; available in 200 ml bottles.
- Omega Royal Food Supplement Omega-3 food supplement derived from caviar; launched in 2016 and recognized with the Innovative Product award at the Golden Mortar Awards.
Companies that use Drogsan Pharmaceuticals
Customer profileNamed customers3 records
Segments10 records
Ideal customer profiles2 records
Drogsan Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Drogsan Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Cumhuriyet UniversitycorePatented Formulation Commercialization Agreement - First time in Turkey a patented formulation developed at a medical faculty was commercialized by a domestic pharmaceutical company. Drogsan commercialized 'Storice' - Strontium + Licorice formulation developed by Sivas Cumhuriyet University Faculty of Medicine Department of Dermatology.
- Rockwell MedicalcoreStrategic collaboration for marketing FDA-approved innovative iron deficiency anemia drug for hemodialysis patients in Turkey and surrounding countries. Drogsan brings 45 years of pharmaceutical experience, corporate infrastructure, successful new product launches, and experienced nephrology team. Rockwell provides innovative parenteral iron technology platform products.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
Drogsan Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Abdi İbrahim: Abdi İbrahim is the largest Turkish pharmaceutical company, operating a broad generic portfolio with strong domestic share and growing exports — the leading domestic competitor against which DROGSAN competes head-to-head.
- Cipla: Cipla is a major Indian-headquartered generics and biosimilars player with an Africa-and-MENA-heavy export mix; it competes with DROGSAN for emerging-market tenders and licensing deals.
- Julphar (Gulf Pharmaceutical Industries): Julphar is a UAE-based generics manufacturer with GCC-anchored approvals and exports across MENA and emerging markets, closely comparable to DROGSAN in target regions, regulatory footprint, and product mix.
- Aristo Pharma: Aristo Pharma is a German generics manufacturer with broad therapeutic coverage and active export operations; it is comparable in product breadth and contract-manufacturing orientation.
- Aurobindo Pharma: Aurobindo is one of India's largest generic manufacturers with a globally diversified export franchise spanning regulated and emerging markets, serving as a comparable on export scale and therapeutic breadth.
- Eczacıbaşı Pharmaceuticals (EIP Eczacıbaşı): Eczacıbaşı İlaç is a leading Turkish pharmaceutical manufacturer with an established export footprint; it competes with DROGSAN domestically and in selected CIS and MENA markets.
- Hikma Pharmaceuticals: Hikma is a Jordan/UK-headquartered generic and specialty pharmaceutical manufacturer with deep MENA and emerging-market distribution and a strong biosimilar/injectables franchise, making it the closest scale and geographic comparable to DROGSAN.
Broad incumbents
- Sandoz (Novartis): Sandoz is the world's largest pure-play generics and biosimilars business; it competes with DROGSAN in regulated and emerging markets across essentially the same therapeutic categories and serves as the global benchmark for the segment.
- Teva Pharmaceutical Industries: Teva is a global generics and specialty leader with broad geographic reach across the same export markets DROGSAN targets; it represents the upper-end scale comparable in the generics-plus-biosimilar space.
- Viatris: Viatris is a US/global generics powerhouse formed from Mylan-Upjohn with strong emerging-market distribution; it competes with DROGSAN in tenders and licensing across many of the same therapeutic categories.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Drogsan Pharmaceuticals social profiles
Digital presenceDrogsan Pharmaceuticals compliance and trust
Trust signalCompliance9 records
Drogsan Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Drogsan Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles4 records
Drogsan Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Drogsan Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Drogsan Pharmaceuticals
What does Drogsan Pharmaceuticals do?
Drogsan Pharmaceuticals manufactures and markets generic and innovative pharmaceutical products across 21 therapeutic categories including antiviral, cardiovascular, respiratory, gastrointestinal, dermatological, neurological, and nephrology treatments. The company operates cGMP-compliant manufacturing facilities producing solid dosage forms (tablets, capsules, sachets) and liquid preparations (syrups, nasal sprays, oral solutions) for distribution through wholesalers, pharmacies, hospitals, and international partners across 30+ countries.
Is Drogsan Pharmaceuticals a public or private company?
Drogsan Pharmaceuticals is a private company. It is classified as family owned and is currently operating.
When was Drogsan Pharmaceuticals founded?
Drogsan Pharmaceuticals was founded in 1975. It employs 251 to 500 people.
Where is Drogsan Pharmaceuticals based?
Drogsan Pharmaceuticals is headquartered in Balgat.
How does Drogsan Pharmaceuticals make money?
Four revenue lines are on record. Generic Pharmaceutical Products are the primary driver. The others are food Supplements, cosmetic Products and licensing and Technology Transfer.
Who are Drogsan Pharmaceuticals's main competitors?
Direct peers on record are Abdi İbrahim, Cipla, Julphar (Gulf Pharmaceutical Industries), Aristo Pharma, Aurobindo Pharma, Eczacıbaşı Pharmaceuticals (EIP Eczacıbaşı) and Hikma Pharmaceuticals. Broad incumbents are Sandoz (Novartis), Teva Pharmaceutical Industries and Viatris.
Does Drogsan Pharmaceuticals have an API?
No public API is recorded for Drogsan Pharmaceuticals.
What industry is Drogsan Pharmaceuticals in?
Drogsan Pharmaceuticals's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIABAL, Generic Hospital & Institutional Products. Its NAICS code is 325412 and its SIC code is 2834.